Genetics of four new HL-A specificities in the Caucasian and Negro populations.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M R Mickey.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The HL-A2 leucocyte antigen was found to be present in a significantly higher percentage of 485 patients with chronic glomerulonephritis than in 428 normal control subjects. No correlation could be shown between any of the ABO groups and chronic glomerulonephritis. There was no statistically significant difference in the frequency of HL-A2 when the controls were compared with 280 patients with a variety of other diseases. The trend toward an excess of HL-A2 positives among patients with glomerulonephritis was also seen in a study of 108 sibships, though the difference fell short of statistical significance. It was concluded that an HL-A2 positive person was about 1.5 times as likely to develop chronic glomerulonephritis as an HL-A2 negative person.
Cytotoxic antibodies against allogeneic lymphocytes were detected in 13 patients after removal of a renal allograft. Antibodies were not detected in seven patients who had grafts in situ for less than two months, but were detected in 13 out of 17 patients who had grafts in situ for longer than two months. The HL-A specificity of these positive sera was compatible with the HL-A antigen mismatch of the donor-recipient pairs in most instances, providing further evidence that such antibodies result from direct sensitization by the allograft and may play some part in renal allograft rejection.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.